GSK sees sales beat forecasts thanks to shingles jab and HIV drugs
The pharmaceutical giant saw revenues drop 8% in the first quarter, but this was better than feared.
The pharmaceutical giant saw revenues drop 8% in the first quarter, but this was better than feared.